Telomir Pharmaceuticals
TELO
33 hedge funds and large institutions have $3.8M invested in Telomir Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
30% more capital invested
Capital invested by funds: $2.91M → $3.8M (+$883K)
22% more funds holding
Funds holding: 27 → 33 (+6)
2.19% less ownership
Funds ownership: 6.52% → 4.33% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$805K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$117K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$117K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$66.7K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$28.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$168K |
| 2 |
SEM
Suncoast Equity Management
Tampa,
Florida
|
-$66.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$46.9K |
| 4 |
Goldman Sachs
New York
|
-$13.5K |
| 5 |
BlackRock
New York
|
-$11.4K |
TELO Hedge Fund Activity: Q2 2026 in Review
33 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q2 2026, worth a combined $3.8M — up 30% from $2.91M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TELO positions and 5 closed out — a net gain of 6 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Capital Management, adding an estimated $805K. The largest seller was Millennium Management, exiting entirely with an estimated $168K sold.
- 33 institutional investors held Telomir Pharmaceuticals (TELO) as of Q2 2026, up from 27 in Q1 2026.
- Funds reported $3.8M of Telomir Pharmaceuticals stock for Q2 2026, up 30% quarter-over-quarter.
- 11 funds opened new Telomir Pharmaceuticals positions in Q2 2026 and 5 closed out, a net change of +6 holders.
- The largest Telomir Pharmaceuticals buyer in Q2 2026 was Vanguard Capital Management, an estimated $805K added.
- The largest Telomir Pharmaceuticals seller in Q2 2026 was Millennium Management, an estimated $168K sold.
Based on aggregated 13F filings for Q2 2026.